A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
2017
Alzheimer's & Dementia
INTRODUCTION- The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, beginning August 1, 2016, is a five year renewal of the current ADNI-2 study. METHODS-ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment (MCI) and AD using innovative technologies such as tau imaging, magnetic resonance imaging (MRI) sequences for connectivity analyses, and a
doi:10.1016/j.jalz.2016.10.006
pmid:27931796
pmcid:PMC5536850
fatcat:sutbyvnlqrhtrbexozepcvsimi